525,000 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Vestal Point Capital LP

Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 525,000 shares of the company’s stock, valued at approximately $3,644,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics during the 1st quarter worth $64,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Zevra Therapeutics by 10.7% in the second quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after purchasing an additional 21,231 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Zevra Therapeutics by 17.9% during the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock valued at $279,000 after purchasing an additional 8,619 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $9.50 on Friday. The firm’s 50 day moving average price is $8.33 and its two-hundred day moving average price is $6.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. As a group, sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.